**Bando Piano Operativo Salute (POS) 2021**


Budget: a seconda della Traiettoria per la quale si partecipa

Il POS, approvato con Delibera del Comitato interministeriale per la programmazione economica (CIPE) n. 15 del 28 febbraio 2018 a valere sul Fondo per lo Sviluppo e la Coesione (FSC) 2014-2020, con una dotazione finanziaria complessiva pari a 200 milioni di euro, si inserisce nel processo unitario di programmazione strategica e operativa per il periodo 2014-2020, in coerenza con la Strategia Nazionale di Specializzazione Intelligente (SNSI) - area di specializzazione “Salute, alimentazione e qualità della vista”, il Programma Nazionale per la Ricerca (PNR) e il Piano Attuativo Salute della SNSI.

È articolato in cinque Traiettorie di sviluppo cui corrispondono specifici Avvisi pubblici nell’ambito delle relative Linee di azione:

- **Traiettoria 1 “Active & Healthy Ageing - Tecnologie per l’invecchiamento attivo e l’assistenza domiciliare”;**
- **Traiettoria 2 “eHealth, diagnostica avanzata, medical device e mini invasività”;**
- **Traiettoria 3 “Medicina rigenerativa, predittiva e personalizzata”;**
- **Traiettoria 4 “Biotecnologia, bioinformatica e sviluppo farmaceutico”;**
- **Traiettoria 5 “Nutraceutica, nutrigenomica e alimenti funzionali”.**

[Link](#)

***

**INTESA SAN PAOLO**

**Fondo di Beneficenza**

**Deadlines: 30 Maggio 2021 (solo per l’Area Medica)**

**Budget: n.d.**

Il "Fondo di Beneficenza ed opere di carattere sociale e culturale", destina una quota degli utili distribuibili alla beneficenza e al sostegno di progetti che hanno come riferimento la solidarietà, l’utilità sociale e il valore della persona. Ogni anno è possibile presentare idee progettuali su tematiche ritenute particolarmente rilevanti e urgenti. Per il biennio 2021-2022 sono indicati 3 Focus principali in Ambito Sociale:
- Supporto psicologico ai malati di Covid e ai soggetti maggiormente colpiti dalla pandemia;
- Formazione e inserimento lavorativo di soggetti fragili, con particolare attenzione per le nuove povertà;
- Supporto agli adolescenti e ai giovani in situazione di fragilità.
Per il biennio 2021-2022 l’intervento del Fondo intende anche porre anche l’attenzione su tutti quei progetti di ricerca in Area medica che hanno come fine il miglioramento della vita degli individui, risolvendo gravi problematiche o rispondendo a bisogni emergenti.
Fatta eccezione per l’Area Medica, ogni altra idea progettuale potrà essere presentate in ogni momento attraverso la piattaforma on-line.

***

Pfizer 2021
Growth Hormone Research

Deadlines: 1 Giugno 2021

Budget: 75000,00 $

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.
The institution and principal investigator (PI) must be based in one of the eligible countries noted above. Only organizations are eligible to receive grants, not individuals or medical practice groups. The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
Applicant must be affiliated with a host institution.
Research projects that will be considered for Pfizer support will advance the medical knowledge of short stature.
Projects submitted may include:
- Morbidities in growth disorders
- Novel strategies including Quality of Life and Patient Reported Outcomes to evaluate and treat growth disorders.
- Comparative pathophysiology of daily vs long-acting growth hormone.
- Innovative methods to evaluate levels of adherence of daily and long-acting growth hormone treatment.
- Novel strategies to address current unmet medical needs in short stature management which could be addressed with long-acting growth hormone treatment.
(Note: Pfizer will not supply study drug)
---

**Pfizer 2021**

**Quality Improvement Grants to Support the Delivery of Gene Therapies to Patients with Rare Disease**

**Deadlines:** 1 Giugno 2021

**Budget:** 500000,00 $ 

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the practice gaps as outlined in the specific RFP.

For all independent quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.

If the project involves multiple departments within an institution and/or between different institutions / organizations / associations.

All institutions must have a relevant role and the requesting organization must have a key role in the project.

For projects offering continuing education credit, the requesting organization must be accredited.

Projects that will be considered for Pfizer support will focus on preparing and/or optimizing multidisciplinary care teams for the integration of gene therapy into the treatment armamentarium for patients with a Rare Disease. Support is available for the development of leadership, best practices, SOP development, site readiness, support and/or training of HCPs within a multidisciplinary team environment to optimize the quality of care for patients who have/will have gene therapy in their treatment armamentarium.

Projects that address recombinant adeno-associated virus gene therapy in Rare Disease and are therapeutic area and disease area agnostic (i.e., platform) will be prioritized.

[Link](#) 

---

**European Research Council (ERC)**

**Starting Grants | ERC-2021-StG**

Open: 25 February 2021
Deadline: 12 April 2021
The ERC Starting Grants are designed to support excellent Principal Investigators at the career stage at which they are starting their own independent research team or programme. Principal Investigators must demonstrate the ground-breaking nature, ambition and feasibility of their scientific proposal.

Starting Grants may be awarded up to a maximum of EUR 1,500,000 for a period of 5 years. The maximum size of the grants is reduced pro rata temporis for projects of a shorter duration. (This does not apply to on-going projects).

Additional funding up to EUR 1,000,000 can be requested in the proposal to cover the following eligible costs when these are necessary to carry out the proposed work: (a) "start-up" costs for Principal Investigators moving to the EU or an Associated Country from elsewhere as a consequence of receiving the ERC grant and/or (b) the purchase of major equipment and/or (c) access to large facilities and/or (d) other major experimental and field work costs, excluding personnel costs.

The Principal Investigators shall have been awarded their first PhD at least 2 and up to 7 years prior to 1 January 2021. Cut-off dates: PhD awarded from 1 January 2014 to 31 December 2018 (inclusive). The eligibility period can be extended beyond 7 years in certain properly documented circumstances.

A competitive Starting Grant Principal Investigator must have already shown the potential for research independence and evidence of maturity, for example by having produced at least one important publication as main author or without the participation of their PhD supervisor. Applicant Principal Investigators should also be able to demonstrate a promising track record of early achievements appropriate to their research field and career stage, including significant publications (as main author) in major international peer-reviewed multidisciplinary scientific journals, or in the leading international peer-reviewed journals of their respective field. They may also demonstrate a record of invited presentations in well-established international conferences, granted patents, awards, prizes, etc.

[Link]

---

Consolidator Grants | ERC-2021-CoG
Open: 11 March 2021
Deadline: 20 April 2021

The ERC Consolidator Grants are designed to support excellent Principal Investigators at the career stage at which they may still be consolidating their own independent research team or programme. Principal Investigators must demonstrate the ground-breaking nature, ambition and feasibility of their scientific proposal.

Consolidator Grants may be awarded up to a maximum of EUR 2,000,000 for a period of 5 years. The maximum size of the grants is reduced pro rata temporis for projects of a shorter duration. (This does not apply to on-going projects).

Additional funding up to EUR 1,000,000 can be requested in the proposal to cover the following eligible costs when these are necessary to carry out the proposed work: (a) "start-up" costs for Principal Investigators moving to the EU or an Associated Country from elsewhere as a consequence of receiving the ERC grant and/or (b) the purchase of major equipment and/or (c) access to large facilities and/or (d) other major experimental and field work costs, excluding personnel costs.

The Principal Investigators shall have been awarded their first PhD at least 2 and up to 7 years prior to 1 January 2021. Cut-off dates: PhD awarded from 1 January 2014 to 31 December 2018 (inclusive). The eligibility period can be extended beyond 7 years in certain properly documented circumstances.
equipment and/or (c) access to large facilities and/or (d) other major experimental and field work costs, excluding personnel costs. The Principal Investigators shall have been awarded their first PhD at least 7 and up to 12 years prior to 1 January 2021. Cut-off dates: PhD awarded from 1 January 2009 to 31 December 2013 (inclusive). The eligibility period can be extended beyond 12 years in certain properly documented circumstances.

A competitive Consolidator Grant Principal Investigator must have already shown research independence and evidence of maturity, for example by having produced several important publications as main author or without the participation of their PhD supervisor. Applicant Principal Investigators should also be able to demonstrate a promising track record of early achievements appropriate to their research field and career stage, including significant publications (as main author) in major international peer-reviewed multidisciplinary scientific journals, or in the leading international peer-reviewed journals of their respective field. They may also demonstrate a record of invited presentations in well-established international conferences, granted patents, awards, prizes, etc.

Link

---

**Advanced Grants | ERC-2021-AdG**

Probable Opening date: 20 Maggio 2021

Probable Deadline: Agosto 2021

---

**European Innovation Council EU Prize for Women Innovators (HORIZON-EIC-2021-WomenInnovatorsPrize)**

Open: 18 March 2021

Deadline: 30 June 2021

Prizes: 50000,00 eur & 100000,00 eur

The opportunities created by novel technologies and disruptive innovations promise to deliver the fair and sustainable recovery Europe needs. But Europe risks missing out on these opportunities if half its population is overlooked as a source of innovation and creative talent.

The EU Prize for Women Innovators celebrates the women entrepreneurs behind game-changing innovations. In doing so, the EU seeks to raise awareness of the need for more female innovators, and create role models for women and girls everywhere.

The prize is awarded to the most talented women entrepreneurs from across the EU and countries associated to Horizon Europe, who have founded a successful company and brought innovation to market. The prize is launched and managed by the European Innovation Council and SMEs Executive Agency, and the winners are chosen by an independent expert jury.

In the ‘Women Innovators’ main category, three prizes of EUR 100 000 each are awarded to the women who, in the opinion of the jury, have excelled in all award criteria and stood out amongst the other applicants. In the second category, one prize of EUR 50 000 is awarded to a promising ‘Rising Innovator’ aged 30 or younger.
Expected Impact: The prizes will boost public awareness of the potential, importance and contribution of women to the innovation ecosystem and create strong role models inspiring other women to become innovators themselves.

https://ec.europa.eu